Edesa Biotech is trading 8.2% down at $4.91 as the stock reverses a sharp, low-catalyst spike seen in recent sessions.
- There are no new company-specific headlines, FDA updates, or earnings reports dated July 28, 2026, to explain the current price action.
- The move appears to be a technical reversal following a period of unexplained volatility, compounded by broader risk-off sentiment in the growth and biotechnology sectors.